Overview of the Story
- Two decades ago, Merck launched Vioxx, a lucrative NSAID, despite awareness of its potential to cause numerous heart attacks.
- Following a surge of legal challenges and the subsequent withdrawal of Vioxx, Merck swiftly introduced Gardasil, an HPV vaccine, in an attempt to mitigate financial losses.
- Gardasil was found to be highly hazardous, yet both Merck and the FDA overlooked disturbing data and continued its promotion, leading to severe adverse effects such as autoimmunity, POTS, infertility, and even death.
- Many of these complications are strikingly similar to those observed with COVID-19 vaccines.
- This article delves into the risks associated with the HPV vaccine, the underlying causes of its dangers — notably its propensity to induce rather than prevent cervical cancer — and the profound oversight by the FDA and CDC. Understanding these dynamics is essential for grasping the broader context of the COVID-19 situation.
Reflections on the Dangers of Gardasil
Before the COVID-19 pandemic, you might have regarded Gardasil, the HPV vaccine, as one of the most dangerous and indefensible vaccines available. The similarities between Gardasil and the COVID-19 vaccines are striking, highlighting a crucial, yet largely overlooked narrative that needs to be revisited.
The Financial Motivations Behind Vioxx
In the world of medicine, the go-to solution for any pain or injury often involves NSAIDs, which, despite their popularity, provide limited relief and carry significant risks. For instance, NSAIDs are responsible for tens of thousands of deaths in the U.S. each year and cause even more serious injuries—an unfortunate fact considering safer alternatives like DMSO exist. To tap into a new market, pharmaceutical companies developed NSAIDs like Vioxx, touted as safer but later revealed to carry severe risks of stroke and heart attacks. Many doctors had already raised alarms about Vioxx in 1999, but despite growing evidence of harm, Merck and the FDA continued to suppress this information. When Vioxx was finally recalled, it was linked to approximately 120,000 deaths.
The Inevitable Consequences of Corporate Practices
As a former FDA scientist lamented, the situation with Vioxx was just business as usual, and another disaster was inevitable. The aftermath saw Merck paying out a $5 billion settlement for Vioxx damages, during which time their CEO received a $37.8 million performance-based bonus. Facing financial strain, Merck pivoted to exploiting decades of research that culminated in the introduction of Gardasil. With aggressive and “award-winning” marketing campaigns, Merck, supported by the FDA, instilled a widespread fear of cervical cancer—a relatively rare disease—to boost vaccine uptake. The strategy was successful, with Gardasil adoption rates soaring from 25.1% in 2007 to 79.3% by 2023, making it a major revenue stream for Merck.
Financial Dynamics of Vaccine Marketing
Like the COVID-19 vaccines, Gardasil’s high cost necessitated substantial government support, including incentives and a $40 million HHS grant to develop persuasive sales tactics for doctors targeting vaccine-hesitant patients. This need for extensive financial assistance from state or federal sources to promote Gardasil underscores a broader pattern observed with the COVID-19 vaccine rollout, reflecting ongoing challenges in vaccine administration and public health funding.
Evaluating Gardasil’s Efficacy
Marketing Driven by Diminished Risk
Merck’s aggressive promotion of Gardasil was largely motivated by the reduced threat of cervical cancer, historically mitigated by the widespread use of Pap smears. The vaccine’s effectiveness against cervical cancer remained theoretical, with Merck convincing the FDA that directly studying cancer was impractical due to the lengthy timelines and potential risks to women. Despite high vaccination rates, with 80% of women receiving it, there has been no corresponding decrease in cervical cancer incidences. Moreover, Gardasil’s marketing efforts have eclipsed other significant cervical cancer risk factors, such as smoking and the use of birth control pills. Intriguingly, the reduction in smoking rates aligns closely with the decline in cervical cancer mortality, suggesting other variables at play beyond HPV.
The Provocation of Disease by Vaccination
Vaccines inherently stress the body and redirect the immune system to respond to the vaccine’s antigens. This diversion can exacerbate other infections if the immune system is already engaged in fighting them. Known since 1893 and demonstrated in various contexts—such as with polio and typhus—this phenomenon underscores the complex interplay between vaccination and disease dynamics. Personal observations and broader patterns reveal that receiving flu shots often precedes flu infections among recipients. Similarly, during the COVID pandemic, severe COVID cases were frequently reported following vaccination.
Gardasil’s Impact on Existing Infections
The HPV vaccine has been implicated in not only the exacerbation of existing HPV-related conditions, such as genital warts, but also in making pre-existing infections more prone to progress to cancer, as evidenced by Gardasil’s trial data. This raises significant concerns about the vaccine’s role in disease progression, highlighting the need for a deeper understanding and reevaluation of its safety and effectiveness in the real-world context.
Overlooked HPV Prescreening and Vaccination Practices
Shifting Vaccination Ages Instead of Precautions
Despite growing concerns, prescreening for HPV prior to vaccination is not commonly recommended. The prevailing approach has been to simply lower the age at which the vaccine is administered, sidestepping the fundamental issue of pre-existing infections which could be exacerbated by vaccination.
Concerns of DNA Contamination in Vaccine Production
The Inherent Risks of Vaccine Manufacturing
I’ve discussed how vaccines can potentially lead to sickness by weakening the immune system, making individuals more vulnerable to existing infections or new ones. Beyond this primary concern, another significant issue arises from the vaccine production process itself, which can be inherently prone to contamination. This reality results in the occasional release of contaminated “hot” lots, which have been known to cause illness or death. This problem was addressed by granting legal immunity to vaccine manufacturers, which complicates accountability.
Contaminants in the HPV Vaccine
Producing vaccines like Gardasil involves the use of synthetic DNA, or plasmids, which are not always completely removed from the final product. This issue has been a consistent problem, particularly highlighted by the presence of hazardous components such as parts of the SV40 virus in these plasmids. These elements can integrate into the human genome, a serious risk that has also been observed with COVID vaccines. Historical precedents like the contamination of early polio vaccines with the cancer-causing SV40 virus, and the government’s decision to distribute it regardless of risks, underscore the potential dangers.
The Broader Impact of Gardasil’s Side Effects
Autoimmune Reactions and Lifelong Disabilities
Gardasil has been linked to a high rate of autoimmune disorders, leading to serious and sometimes permanent disabilities among recipients. Similar to reports from COVID vaccine recipients, there are thousands of documented cases of individuals suffering severe health declines after receiving the Gardasil vaccine. One of the most frequently reported side effects has been POTS (Postural Orthostatic Tachycardia Syndrome), a condition that causes significant lightheadedness upon standing and was notably prevalent in Gardasil trials.
Questionable Trial Practices and Vaccine Approval
Merck’s handling of Gardasil trials raises further concerns. By using the vaccine’s own adjuvant as a “placebo,” the trials may have obscured the true extent of harm caused by the vaccine. The observed adverse effects in the vaccine group were not significantly higher than those in the placebo group, leading to conclusions that these were coincidental and unrelated to the vaccine. This methodology brings to light serious ethical and scientific concerns regarding the evaluation of vaccine safety.
Safety Versus Efficacy: A Misguided Focus
Compromising Safety for Immune Response
Regulatory bodies often prioritize the strength of an antibody response in determining a vaccine’s efficacy, which can lead to manufacturers enhancing the immune response at the expense of safety. In the case of Gardasil, an untested and potent adjuvant was used, which resulted in nearly half of the participants in Merck’s trials developing new medical conditions, including severe autoimmune disorders like Guillain-Barré syndrome and multiple sclerosis. This highlights a troubling trade-off in vaccine development, where the drive for efficacy overshadows the need for safety.
Analyzing the Death Rates Associated with Vaccinations
Sudden Deaths Post-Vaccination
Significant attention has been drawn to the surge of unexplained, often sudden deaths among the youngest and healthiest populations following the release of COVID vaccines. In contrast, less attention has been given to similar patterns observed in the initial Gardasil trials, where out of 21,458 vaccine recipients, 10 died, and out of the placebo group, 7 died—including 7 deaths from car accidents, potentially triggered by POTS symptoms causing drivers to faint. Yet, despite the Gardasil mortality rate (8.5 per 10,000) being nearly double the background death rate for girls and young women (4.37), the FDA expressed no concern.
The Broader Medical and Financial Impacts of Gardasil
Gardasil’s potential neurological side effects could lead to psychiatric issues, funneling young women further into the medical sales pipeline—a phenomenon I have observed firsthand. Additionally, many patients develop expensive, lifelong autoimmune disorders post-vaccination, often failing to connect the dots until highlighted by a professional. This underlines the significant risks vaccines may carry, outweighing their benefits, a fact often overlooked by regulators during the approval processes, as seen with both Gardasil and COVID-19 vaccines.
Regulatory Responses to Vaccine Concerns
Inadequate Handling of Gardasil’s Toxicity
Once Gardasil hit the market, the FDA and CDC were overwhelmed with adverse reaction reports. Instead of acknowledging these, they reinforced their support for the vaccine, creating complex steps to protect it. This response was a precursor to similar strategies employed with the COVID-19 vaccines, even as their harmful effects became widely recognized, and the original virus strain it targeted became extinct.
Flawed Studies and Misleading Public Assurance
In 2009, following public outcry over severe adverse events linked to HPV vaccines, the FDA and CDC launched a study analyzing all VAERS reports from Gardasil’s approval in mid-2006 through the end of 2008. The study revealed a reporting rate for Gardasil three times higher than for all other vaccines combined, with most reports submitted by representatives of Merck, Gardasil’s manufacturer. Despite these red flags, the study concluded that the public’s heightened awareness, stimulated by media, accounted for the high report rate, asserting that Gardasil’s safety profile was consistent with trial data without substantiating this claim. This study was later used as proof of Gardasil’s safety by health authorities and media, a familiar narrative mirrored in the response to COVID-19 vaccine concerns.
Conclusion: The Ethical Dilemmas of Vaccine Deployment
Historical Precedents and Modern Implications
The predatory tactics of the pharmaceutical industry often begin with testing on vulnerable groups before broadening to more extensive applications. This pattern was evident in the unethical clinical trials conducted overseas with Gardasil, mirrored by the controversial childhood vaccine mandates in the U.S. and the disastrous military anthrax vaccine campaign. These actions previewed the strategies used during the COVID-19 pandemic, reflecting a long-standing trend of exploiting crises for regulatory overreach, which historically dates back to the smallpox vaccine mandates.
Risk vs Benefit: A Critical Evaluation
Gardasil’s Alarming Risk-Benefit Ratio
When analyzing the data, Gardasil’s risk-benefit ratio is startlingly poor. In England, Gardasil may have saved 0.6 lives per 10,000 and only 0.2 per 10,000 in the U.S., yet it caused at least 4.13 deaths per 10,000 and severe autoimmune disorders in at least 230 per 10,000 recipients. These figures do not account for other subtle, long-term complications and impacts on fertility. Such statistics reinforce the belief that much of modern medicine functions like a sales funnel, pushing patients into costly, lifelong treatments at the cost of their overall well-being.